Researchers conducting clinical trials designed to improve autism treatment and management may receive substantial funding through the FY2026 Autism Research Program Clinical Trial Award.

The programme supports trials ranging from early proof-of-concept work to larger studies evaluating efficacy in defined populations.

A standard Clinical Trial Award can provide up to $1.5 million.

The Partnering Principal Investigator Option for an Early-Career Investigator can provide up to $1.75 million.

Projects can run for up to four years.

The required pre-application stage closed July 27, 2026. Therefore, the October 22 deadline is only for invited applicants.

What Can the Clinical Trial Evaluate?

Eligible trials may evaluate approaches such as:

• New products;
• Pharmacological agents;
• Biologics;
• Medical devices;
• Clinical guidance;
• Behavioral or healthcare approaches;
• Emerging technologies.

The study should have strong potential to improve autism treatment, management or quality of life.

What Does the Programme Want to Achieve?

The Autism Research Program places emphasis on research that addresses meaningful needs identified by the autism community.

Projects should be capable of influencing real-world outcomes rather than simply producing another academic publication.

Potential areas include:

• Treatment;
• Healthcare access;
• Quality of life;
• Evidence-based practice;
• Lifespan needs;
• Issues affecting military families;
• Emerging clinical technologies.

Community Collaboration Is Required

FY26 Clinical Trial Award applications must include meaningful community collaboration.

At least one community partner should participate, such as:

• An Autistic individual;
• Caregiver;
• Representative of an autism organisation;
• Community advocate.

The relationship should continue throughout the project.

The partner should help shape decisions rather than simply attend occasional meetings.

Preliminary Data Are Important

Clinical trials require sufficient supporting evidence to justify exposing human participants to the proposed intervention.

The application should demonstrate:

• Scientific rationale;
• Preliminary evidence;
• Feasibility;
• Statistical design;
• Appropriate endpoints;
• Risk management.

The programme also expects a transition plan explaining what happens if the study succeeds.

Partnering PI Option

The programme includes a special route combining an experienced investigator with an Early-Career Investigator.

The objective is to support both impactful autism research and future research leadership.

This option carries the higher $1.75 million cost cap.

Funding

Standard option:

Up to $1.5 million

Early-Career Partnering PI option:

Up to $1.75 million

Maximum project period:

4 years

The programme expects approximately $3.25 million in total funding.

Current Status

Pre-application deadline: July 27, 2026, closed.

Invitations issued: August 28, 2026.

Full application deadline: October 22, 2026.

Current applicants: Invited teams only.

Apply Here: Apply through the FY26 Autism Research Program portal
The Grants.gov opportunity number is HT942526ARPCTA. Autism Clinical Trial Award on Grants.gov

Researchers who did not submit the July preproposal should monitor the next Autism Research Program funding cycle rather than attempting to enter at the October stage.